WallStreetZenWallStreetZen

NASDAQ: MYGN
Myriad Genetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MYGN

Based on 3 analysts offering 12 month price targets for Myriad Genetics Inc.
Min Forecast
$22.00+10.22%
Avg Forecast
$24.00+20.24%
Max Forecast
$25.00+25.25%

Should I buy or sell MYGN stock?

Based on 3 analysts offering ratings for Myriad Genetics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 33.33%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MYGN stock forecasts and price targets.

MYGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Raymond James
Bottom 2%
2
BuyUpgrades$25.00+25.25%2023-01-18
SVB Leerink
Bottom 2%
2
HoldMaintains$25.00+25.25%2022-11-02
Stephens & Co.
Bottom 17%
17
HoldInitiates Coverage On$22.00+10.22%2022-10-06
Anonymous
Goldman Sachs
Strong SellMaintains$23.00+15.23%2022-04-19

1 of 1

Forecast return on equity

Is MYGN forecast to generate an efficient return?
Company
N/A
Industry
-21.44%
Market
47.84%

Forecast return on assets

Is MYGN forecast to generate an efficient return on assets?
Company
N/A
Industry
12%

MYGN earnings per share forecast

What is MYGN's earnings per share in the next 1 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.25

MYGN revenue forecast

What is MYGN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$684.4M+3.48%
Avg 2 year Forecast
$743.6M+12.43%
Avg 3 year Forecast
$805.7M+21.81%
MYGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MYGN revenue growth forecast

How is MYGN forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
3.04%
Industry
5.62%
Market
70.6%
MYGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MYGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MYGN vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
MYGN$19.96$24.00+20.24%Hold
NEO$12.55$18.63+48.41%Buy
TWST$25.31$33.80+33.54%Buy
RDNT$21.55$40.00+85.61%Buy
ME$2.69$5.50+104.46%Buy
View Top Diagnostic & Research Stocks

Myriad Genetics Stock Forecast FAQ

Is Myriad Genetics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MYGN) stock is to Hold MYGN stock.

Out of 3 analysts, 0 (0%) are recommending MYGN as a Strong Buy, 1 (33.33%) are recommending MYGN as a Buy, 2 (66.67%) are recommending MYGN as a Hold, 0 (0%) are recommending MYGN as a Sell, and 0 (0%) are recommending MYGN as a Strong Sell.

If you're new to stock investing, here's how to buy Myriad Genetics stock.

What is MYGN's earnings growth forecast for 2023-2023?

(NASDAQ: MYGN) Myriad Genetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 33.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 84.98%.

Myriad Genetics's earnings in 2023 is -$77,300,000.

In 2023, MYGN is forecast to generate -$20,258,454 in earnings, with the lowest earnings forecast at -$34,844,541 and the highest earnings forecast at -$10,534,396.

What is MYGN's revenue growth forecast for 2023-2024?

(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 3.04% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.6%.

Myriad Genetics's revenue in 2023 is $661,400,000.On average, 1 Wall Street analysts forecast MYGN's revenue for 2023 to be $55,459,543,670, with the lowest MYGN revenue forecast at $55,459,543,670, and the highest MYGN revenue forecast at $55,459,543,670. On average, 4 Wall Street analysts forecast MYGN's revenue for 2023 to be $60,255,286,969, with the lowest MYGN revenue forecast at $60,037,954,274, and the highest MYGN revenue forecast at $60,475,536,881.

In 2024, MYGN is forecast to generate $65,284,893,860 in revenue, with the lowest revenue forecast at $64,632,571,642 and the highest revenue forecast at $65,937,216,079.

What is MYGN's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: MYGN) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 12%.

What is MYGN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MYGN price target, the average MYGN price target is $24.00, with the highest MYGN stock price forecast at $25.00 and the lowest MYGN stock price forecast at $22.00.

On average, Wall Street analysts predict that Myriad Genetics's share price could reach $24.00 by Jan 18, 2024. The average Myriad Genetics stock price prediction forecasts a potential upside of 20.24% from the current MYGN share price of $19.96.

What is MYGN's Earnings Per Share (EPS) forecast for 2023-2023?

(NASDAQ: MYGN) Myriad Genetics's current Earnings Per Share (EPS) is -$0.97. In 2023, MYGN's EPS is forecast to hit -$0.25 (min: -$0.43, max: -$0.13).

What is MYGN's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: MYGN) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.